Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system.
Genomic methylation patterns of Dunning R-3327 cell lines anaplastic tumor-1 (AT-1), anaplastic tumor-3 (AT-3), metastasis-lymph and lung (Mat-LyLu) and metastasis-lung (Mat-Lu), and Mat-LyLu cells treated with difluoromethylornithine (DFMO), and retinoic acid (RA) have been analyzed. Each cell line was digested with HpaII and MspI restriction endonuclease enzymes to characterize methylation patterns, at the interior cytosine of the sequence CmCGG. Identical molecular weight banding patterns were found for both HpaII and MspI digests in normal dorsal prostate (NDP) used as a control. Both the treated and non-treated Dunning R-3327 cells digested with HpaII and MspI, displayed similar banding profiles from those seen in NDP solid tissues, indicative of a progressive loss of methylation at CCGG sites.
Blount
L V
LV
Department of Biological Sciences, Clark Atlanta University, Atlanta, GA 30314, USA.
Cooke
D B
DB
D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism*; D000518:Eflornithine / Q000494:pharmacology; D006801:Humans; D008297:Male; D008745:Methylation / Q000187:drug effects; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism*; D012016:Reference Values; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D014212:Tretinoin; D000518:Eflornithine